Overview
Mirada Medical is a global leader in advanced medical imaging software, specializing in AI-driven solutions for oncology and radiotherapy. As of 2026, the company has solidified its market position by leveraging its proprietary Deep Learning Contouring (DLCExpert) and Deformable Image Registration (DIR) technologies to automate the highly labor-intensive process of organ-at-risk (OAR) segmentation. Their technical architecture is built on a vendor-neutral platform, allowing seamless integration with existing PACS, DICOM RT, and treatment planning systems (TPS). Mirada's solutions, such as RTx and CaseWorks, utilize sophisticated convolutional neural networks (CNNs) trained on vast, curated clinical datasets to provide high-accuracy auto-segmentation that meets or exceeds clinician performance. The platform's 2026 roadmap emphasizes 'Adaptive Radiotherapy' (ART) support, enabling real-time adjustments to treatment plans based on anatomical changes detected during the course of therapy. By automating routine tasks, Mirada allows clinicians to focus on complex decision-making, significantly reducing the time from diagnosis to treatment while improving the consistency and quality of care across multi-site hospital networks.